Table 2 Comparison of general information between TD and non-TD subgroups
From: Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy in advanced lung cancer
General information | TD subgroup | Non-TD subgroup | p |
|---|---|---|---|
(n = 39) | (n = 81) | ||
Sex (male, n (%)) | 29 (74.4%) | 64 (79.0%) | 0.567 |
Age (x ± s) | 63.21 ± 9.75 | 63.78 ± 8.87 | 0.749 |
< 65 (n (%)) | 22 (56.4%) | 48 (59.3%) | 0.767 |
BMI (x ± s) | 23.87 ± 3.72) | 23.62 ± 2.84 | 0.704 |
< 18.5 (n (%) | 4 (10.3%) | 1 (1.2%) | 0.436 |
18.5 ≤ X ≤ 23.9 (n (%)) | 13 (33.3%) | 44 (54.3%) | |
24.0 ≤ X ≤ 27.9 (n (%)) | 16 (41.0%) | 28 (34.6%) | |
≥ 28.0 (n (%)) | 6 (15.4%) | 8 (9.9%) | |
Smoking history (n (%)) | |||
 Never | 16 (41.0%) | 34 (42.0%) | 0.959 |
 Currently | 19 (48.7%) | 40 (49.4%) | |
 Quit | 4 (10.3%) | 7 (8.6%) | |
Clinical Stage (n (%)) | |||
 Stage 3 (%) | 7 (17.9%) | 13 (16.0%) | 0.794 |
 Stage 4 (%) | 32 (82.1%) | 68 (84.0%) | |
Tumor type (n (%)) | |||
 NSCLC | 24 (61.5%) | 52(64.2%) | 0.777 |
 SCLC | 15 (38.5%) | 29 (35.8%) | |
PS score (n (%)) | |||
 1 score | 23 (59.0%) | 50 (61.7%) | 0.772 |
 2 score | 16 (41.0%) | 31 (38.3%) | |
Metastasis (n (%)) | |||
 Bone | 9 (23.1%) | 22 (27.2%) | 0.632 |
 Brain | 4 (10.3%) | 13 (16.0%) | 0.394 |
 Liver | 6 (15.4%) | 10 (12.3%) | 0.646 |
Combination therapy (n (%)) | |||
 Chemotherapy | 31 (79.50%) | 58 (71.6%) | 0.356 |
 Chemotherapy + bevacizumab | 8 (20.5%) | 23 (28.4%) | |